Abstract
Several association studies have indicated the insulin receptor substrate-1 (IRS-1) gene G972R variant as a genetic risk factor for insulin resistance, particularly in presence of obesity. A few studies have also suggested a possible effect of the G972R variant on insulin secretion. The aim of this study was to evaluate the role of the IRS-1 gene G972R variant in 61 subjects with “uncomplicated” obesity [i.e. without diabetes, hypertension, dyslipidemia, coronary artery disease (CAD)], studied by hyperinsulinemic-euglycemic clamp. The presence of the G972R variant, detected in real-time with LightCycler hybridisation probes, was related to the indexes of insulin sensitivity. Furthermore, the possible role of this variant on insulin secretion was studied by means of insulin release indexes derived from oral tolerance test (OGTT). Twenty-four point five percent (24.5%) (no.=15) of the obese subjects proved to be carriers of the G972R variant. M index (p<0.05), non-oxidative glucose (p<0.01), insulin clearance (p<0.03) and insulin sensitivity index (ISI) (p<0.005) were all significantly reduced in G972R carriers compared to non-carriers, indicating a significant reduction in insulin sensitivity in carriers of the variant. A logistic regression analysis confirmed the independent association between the G972R variant and reduced insulin sensitivity (p<0.03). The interaction between obesity and the G972R variant was also independently associated with a reduced insulin sensitivity (p<0.005), suggesting that obesity and G972R variant were more than additive in predicting insulin resistance. The analysis of insulin release indexes did not show any significant differences. Our results demonstrate the association of the G972R variant of the IRS-1 gene with reduced insulin sensitivity in obese subjects, and indicate a possible interaction between the IRS-1 variant and obesity in worsening of insulin sensitivity.
Similar content being viewed by others
References
Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest 2002, 32: 3–13.
Baroni MG, Arca M, Sentinelli F, et al. The G972R variant of the Insulin Receptor Substrate-1 (IRS-1) gene, body fat distribution and insulin-resistance. Diabetologia 2001, 44: 367–72.
Clausen JO, Hansen T, Bjorbaek C, et al. Insulin resistance: interactions between obesity and a common variation of insulin receptor substrate-1. Lancet 1995, 346: 397–402.
Hitman GA, Hawrami K, McCarthy MI. Insulin receptor substrate-1 gene mutations in NIDDM: implications for the study of polygenic disease. Diabetologia 1995, 38: 481–6.
Hribal ML, Federici M, Porzio O, et al. The Gly →Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clin Endocrinol Metab 2000, 85: 2004–13.
Almind K, Inoue G, Pedersen O, Kahn CR. A common aminoacid polymorphism in insulin receptor substrate-1 causes impaired insulin signalling. J Clin Invest 1996, 97: 2569–75.
Le Fur S, Le Stunff C, Bougneres P. Increased insulin resistance in obese children who have both 972 IRS-1 and 1057 IRS-2 polymorphisms. Diabetes 2002, 51 (Suppl 3): S304–7.
Baroni MG, D’Andrea MP, Montali A, et al. A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 1999, 19: 2975–80.
Marini MA, Frontoni S, Mineo D, et al. The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 2003, 88: 3368–71.
Ito K, Katsuki A, Furuta M, et al. Insulin sensitivity is not affected by mutation of codon 972 of the human IRS-1 gene. Horm Res 1999, 52: 230–4.
Koch M, Rett K, Volk A, et al. Amino acid polymorphism Gly 972 Arg in IRS-1 is not associated to lower clamp-derived insulin sensitivity in young healthy first degree relatives of patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 1999, 107: 318–22.
Stumvoll M, Fritsche A, Volk A, et al. The Gly972Arg polymorphism in the insulin receptor substrate-1 gene contributes to the variation in insulin secretion in normal glucosetolerant humans. Diabetes 2001, 50: 882–5.
Porzio O, Federici M, Hribal ML, et al. The Gly972→Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic beta cells. J Clin Invest 1999, 104: 357–64.
Matsuda M, DeFronzo RA Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22: 1462–70.
Leonetti F, Iacobellis G, Ribaudo MC, Zappaterreno A, Missori S and Di Mario U. Correlation between leptin and insulin sensitivity in uncomplicated obesity: the role of body mass index. European Group for the Study of Insulin Resistance (EGIR) Meeting, May 2002, A12: 23.
Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000, 23: 295–301.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979, 237: E214–22.
Natali A, Toschi E, Camastra S, Gastaldelli A, Groop L, Ferrannini E. Determinants of postabsorptive endogenous glucose output in non-diabetic subjects. European Group for the Study of Insulin Resistance (EGIR). Diabetologia 2000, 43: 1266–72.
Wittwer CT, Ririe KM, Andrew RV, David DA, Gundry RA, UJ Balis. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. Biotechniques 1997, 22: 176–81.
Ririe KM, Rasmussen RP, CT Wittwer. Product differentiation by analysis of DNA melting curves during the Polymerase Chain Reaction. Anal Biochem 1997, 245: 154–60.
Imai Y, Fusco A, Suzuki V, et al. Variant sequences of insulin receptor substrate-1 in patients with non-insulin diabetes mellitus. J Clin Endocrol Metab 1994, 79: 1655–8.
Zhang Y, Wat N, Stratton IM, et al. UKPDS 19: heterogeneity in NIDDM: separate contributions of IRS-1 and beta 3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. UK Prospective Diabetes Study. Diabetologia 1996, 3: 1505–11.
American Diabetes Association: Consensus development conference on insulin-resistance. Diabetes Care 1998, 21: 310–4.
Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia 2003, 46: 990–5.
Yamada K, Yuan X, Ishiyama S, et al. Codon 972 polymorphism of the insulin receptor substrate-1 gene in impaired glucose tolerance and late-onset NIDDM. Diabetes Care 1998, 21: 753–6.
,t Hart LM, Nijpels G, Dekker JM, Maassen JA, Heine RJ, van Haeften TW. Variations in insulin secretion in carriers of gene variants in IRS-1 and -2. Diabetes 2002, 51: 884–7.
Federici M, Pandolfi A, De Filippis EA, et al. A.G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 2004, 27; 109: 399–405.
Abe H, Yamada N, Kamata K, et al. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 1998, 101: 1784–8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Prof. Di Mario died suddenly in February 2004, after completing work on this paper, and this work is dedicated to him.
Rights and permissions
About this article
Cite this article
Baroni, M.G., Leonetti, F., Sentinelli, F. et al. The G972R variant of the insulin receptor substrate-1 (IRS-1) gene is associated with insulin resistance in “uncomplicated” obese subjects evaluated by hyperinsulinemic-euglycemic clamp. J Endocrinol Invest 27, 754–759 (2004). https://doi.org/10.1007/BF03347518
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347518